不同剂量瑞舒伐他汀对急性冠脉综合征患者的临床疗效及对hs-CRP的影响  

Clinical efficacy of different doses of rosuvastatin treatment and its influence on high-sensitivity C-reactive protein(hs-CRP) in patients with acute coronary syndrome

作　　者：怯红晓[1] 邵芳[1] 于维雅[1] 宋贵峰 王蕾[1] 

机构地区：[1]河南省平顶山市平煤集团总医院心血管内科,河南平顶山467000

出　　处：《中国现代医生》2013年第1期33-34,36,共3页China Modern Doctor

摘　　要：目的观察瑞舒伐他汀对急性冠脉综合征(ACS)患者的临床疗效及对血清中高敏C反应蛋白(hs-CRP)的影响。方法选取2010年11月～2012年3月于我院心内科住院的256例ACS患者,其中试验组(n=130)自入院始服用瑞舒伐他汀20 mg/d,对照组(n=126)自入院始服用瑞舒伐他汀10 mg/d,观察住院期间及4周内的主要不良心脏事件(MACE),同时采用酶联免疫吸附法测定两组患者服用瑞舒伐他汀前后血清hs-CRP水平。结果两组患者住院期间及服瑞舒伐他汀4周后,在不良心脏事件(MACE)发生率方面,试验组低于对照组,差异有统计学意义(P<0.05);肌溶解发生率方面差异无统计学意义;试验组与对照组治疗前后血清hs-CRP水平均显著降低,差异有统计学意义(P<0.05)。结论瑞舒伐他汀可显著降低ACS患者血清hs-CRP水平,安全性好,能改善ACS患者的预后。Objective To observe the clinical efficacy of different doses of rosuvastatin treatment and its influence on high-sensitivity C-reactive protein （hs-CRP） in patients with acute coronary syndrome. Methods A total of 256 patients were divided into two groups randomly： experimental group （n = 130, rosuvastatin was 20 mg/d based routine therapy） and control group （n = 126, rosuvastatin was 10 mg/d based routine therapy）. Major adverse cardiac events （MACE） rates during in hospital and within four weeks were analyzed and compared between the two groups. Enzyme-linked immynosorbent assay was used to measue levels of hs-CRP in 256 patients before and after treatment. Results The MACE fate was more significantly lower for the experimental group than the control group （P 〈 0.05）. It was no signif- icantly differefee between the two groups in muscle dissolved. Level of hs-CRP was more decreased for the experi- mental group than the control group （P 〈 0.05）. Conclusion Rosuvastatin can reduce the incidence of MACE and the level of hs-CRP in patients with acute coronary syndrome, and has more safety.

关 键 词：瑞舒伐他汀 急性冠脉综合征 高敏C反应蛋白 不良心脏事件 

分 类 号：R541.4[医药卫生—心血管疾病]